Drug Profile
Research programme: NMDA receptor antagonists - Sosei R&D
Alternative Names: AD-529; ED-1812; NMDA antagonists research programme - ArakisLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Sosei R&D
- Class
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neuropathic pain; Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in United Kingdom (Transdermal)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in United Kingdom
- 30 Aug 2005 Arakis has been acquired by Sosei